Author: Sarah Baker

Medical device trials increasingly incorporate adaptive randomisation to improve efficiency and patient outcomes. Two main approaches have emerged: treatment-adaptive randomisation (TAR), which modifies allocation probabilities at pre-planned interim analyses, and response-adaptive randomisation (RAR), which updates allocations continuously based on patient outcomes. The choice between these methods depends on trial characteristics including endpoint timing, data infrastructure, regulatory requirements, and scientific objectives.…

While a majority of biomedical and public health research still maintains a linear reductive approach to arrive at empiric insight, reality is in most cases neither of these things. A complex adaptive systems approach, like reality, is non-linear and high dimensional. There are many benefits from taking a linear cause-effect reductivist approach in that the complex problem and it’s solution…